Your browser doesn't support javascript.
loading
Echocardiographic features of left ventricular dysfunction and outcomes in chronic kidney disease.
Ou, Shuo-Ming; Chao, Chieh-Ju; Tsai, Ming-Tsun; Lee, Kuo-Hua; Tseng, Wei-Cheng; Bin, Pin-Jie; Lin, Yao-Ping; Hsu, Chien-Yi; Tarng, Der-Cherng.
Affiliation
  • Ou SM; Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Chao CJ; School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Tsai MT; Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Lee KH; School of Medicine, College of Medicine, National Yang-Ming University, Taipei, Taiwan.
  • Tseng WC; Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan.
  • Bin PJ; Department of Cardiovascular Diseases, Mayo Clinic Rochester, Rochester, Minnesota, USA.
  • Lin YP; Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Hsu CY; School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Tarng DC; Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Heart ; 109(2): 134-142, 2022 12 22.
Article in En | MEDLINE | ID: mdl-36371660
OBJECTIVE: Heart failure (HF) imposes a substantial burden and the prevalence of HF is high in patients with chronic kidney disease (CKD). HF results in multiple hospital admissions, but whether HF subtypes worsen long-term outcomes and renal function in patients with CKD remains inconclusive. METHODS: The study comprised 10 904 patients with CKD aged ≥20 years who underwent echocardiography between 1 January 2011 and 31 December 2018. The patients were stratified into four groups: non-HF, HF with reduced ejection fraction (HFrEF), HF with mildly reduced ejection fraction (HFmrEF) and HF with preserved ejection fraction (HFpEF). The primary end points were all-cause mortality, major adverse cardiovascular events (MACEs) and adverse renal outcomes. RESULTS: In inverse probability of treatment weighting-adjusted method, the risk of all-cause mortality and MACEs relative to the non-HF group was greatest in the HFrEF group (HR 3.18 (95% CI 2.57 to 3.93) and HR 3.83 (95% CI 3.20 to 4.59)), followed by the HFmrEF (HR 2.75 (95% CI 2.22 to 3.42) and HR 3.08 (95% CI 2.57 to 3.69)) and HFpEF (HR 1.85 (95% CI 1.59 to 2.15) and HR 2.43 (95% CI 2.16 to 2.73) groups. In addition, the HFrEF group had the greatest risks of end-stage renal disease (HR 2.58 (95% CI 1.94 to 3.44)) compared with other groups. CONCLUSIONS: HF is associated with subsequent worse clinical outcomes, which may be more pronounced in patients with HFrEF, followed by those with HFmrEF and those with HFpEF relative to non-HF group.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ventricular Dysfunction, Left / Renal Insufficiency, Chronic / Heart Failure Type of study: Risk_factors_studies Limits: Humans Language: En Journal: Heart Journal subject: CARDIOLOGIA Year: 2022 Document type: Article Affiliation country: Taiwan Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ventricular Dysfunction, Left / Renal Insufficiency, Chronic / Heart Failure Type of study: Risk_factors_studies Limits: Humans Language: En Journal: Heart Journal subject: CARDIOLOGIA Year: 2022 Document type: Article Affiliation country: Taiwan Country of publication: United kingdom